IMPC phenotypes (gene matching)
Hprt1-CAG-LSL-ROCK2:ER
| Status | Available to order |
| EMMA ID | EM:11383 |
| Citation information | RRID:IMSR_EM:11383 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | Hprt1-CAG-LSL-ROCK2:ER |
| Alternative name | Hprt-CAG-LSL-ROCK2:ER |
| Strain type | Targeted Mutant Strains : Conditional mutation |
| Allele/Transgene symbol | Hprt1tm-(CAG-ROCK2/ERT) |
| Gene/Transgene symbol | Hprt1 |
Information from provider
| Provider | Michael Olson |
| Provider affiliation | Cancer Research UK Beatson Institute |
| Genetic information | Hprt1-CAG-LSL-ROCK2:ER |
| Phenotypic information | Homozygous:The Hprt1-CAG-LSL-ROCK2:ER targeted transgene enables cre recombinase-inducible expression of a conditionally-active fusion between the ROCK2 kinase domain and the hormone-binding domain of a mutated estrogen receptor (ROCK2:ER), which then requires administration of estrogen analogues such as tamoxifen or 4-hydroxytamoxifen to elicit kinase activity. Given the X-chromosome location, homozygous females have one active copy due to X-chromosome inactivation, while males cannot be homozygous.Heterozygous:Hprt1-CAG-LSL-ROCK2:ER enables cre recombinase-inducible expression of a conditionally-active fusion between the ROCK2 kinase domain and the hormone-binding domain of a mutated estrogen receptor (ROCK2:ER), which then requires administration of estrogen analogues such as tamoxifen or 4-hydroxytamoxifen to elicit kinase activity. Males can only be hemizygous, heterozygous females may display mosaic patterns of expression due to X-chromosome inactivation. |
| References | None available |
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Disease and phenotype information
MGI phenotypes (gene matching)
- decreased hematocrit / MGI
- increased leukocyte cell number / MGI
- increased neutrophil cell number / MGI
- abnormal small intestine morphology / MGI
- abnormal liver morphology / MGI
- abnormal branching of the mammary ductal tree / MGI
- enlarged spleen / MGI
- spleen hyperplasia / MGI
- enlarged lymph nodes / MGI
- tremors / MGI
- convulsive seizures / MGI
- abnormal lung morphology / MGI
- decreased body weight / MGI
- decreased anxiety-related response / MGI
- ataxia / MGI
- hypoactivity / MGI
- impaired coordination / MGI
- abnormal gait / MGI
- short stride length / MGI
- decreased exploration in new environment / MGI
- limb grasping / MGI
- abnormal motor coordination/balance / MGI
- abnormal hematopoietic system physiology / MGI
- hyperglycemia / MGI
- anemia / MGI
- cardiac hypertrophy / MGI
- increased mammary adenocarcinoma incidence / MGI
- abnormal reflex / MGI
- seizures / MGI
- abnormal motor capabilities/coordination/movement / MGI
- premature death / MGI
- abnormal definitive hematopoiesis / MGI
- abnormal brain morphology / MGI
- no abnormal phenotype detected / MGI
- neurodegeneration / MGI
- abnormal spleen white pulp morphology / MGI
- abnormal hematopoietic system morphology/development / MGI
- abnormal megakaryocyte progenitor cell morphology / MGI
- hepatic steatosis / MGI
- decreased vertical activity / MGI
- increased heart weight / MGI
- increased systemic arterial blood pressure / MGI
- albuminuria / MGI
- decreased erythrocyte cell number / MGI
- increased urine protein level / MGI
- impaired social transmission of food preference / MGI
- no phenotypic analysis / MGI
- phenotypic reversion / MGI
- abnormal dopaminergic neuron morphology / MGI
- astrocytosis / MGI
- abnormal depression-related behavior / MGI
- decreased tumor growth/size / MGI
- abnormal nervous system morphology / MGI
- abnormal cardiac muscle relaxation / MGI
- neuronal intranuclear inclusions / MGI
- abnormal myocardial fiber physiology / MGI
- abnormal Paneth cell morphology / MGI
- decreased B cell number / MGI
- decreased cardiac muscle contractility / MGI
- glomerulosclerosis / MGI
- abnormal podocyte morphology / MGI
- muscle phenotype / MGI
- homeostasis/metabolism phenotype / MGI
- endocrine/exocrine gland phenotype / MGI
- behavior/neurological phenotype / MGI
- immune system phenotype / MGI
- taste/olfaction phenotype / MGI
- hematopoietic system phenotype / MGI
- jerky movement / MGI
- thrombocytosis / MGI
- decreased ventricle muscle contractility / MGI
- decreased mean corpuscular hemoglobin concentration / MGI
- decreased dopamine level / MGI
- abnormal podocyte slit diaphragm morphology / MGI
- absent podocyte slit diaphragm / MGI
- podocyte foot process effacement / MGI
- increased megakaryocyte cell number / MGI
- abnormal spatial reference memory / MGI
- abnormal spatial working memory / MGI
- abnormal splenic cell ratio / MGI
- abnormal physiological response to xenobiotic / MGI
- abnormal enterocyte proliferation / MGI
- abnormal enterocyte apoptosis / MGI
- abnormal neuron differentiation / MGI
- increased mammary gland tumor incidence / MGI
- myeloid hyperplasia / MGI
- expanded mesangial matrix / MGI
- mesangial cell hyperplasia / MGI
- abnormal habituation to a new environment / MGI
- abnormal ceramide level / MGI
- decreased brain choline acetyltransferase activity / MGI
- decreased brain tyrosine 3-monooxygenase activity / MGI
- decreased vascular endothelial cell proliferation / MGI